Author: Elisabet Martin Garcia (Spain)
Co-authors: Jose Javier Chavarri García, Maria Klecheva Maksimova, José Luis del Rio Mayor
Purpose
The main challenge was to maintain our patient with non-infectious uveitic macular edema under a sustained treatment avoiding macular edema recurrences.
Setting/Venue
Macular edema is one of the main causes that leads to visual acuity loss in patients with uveitis. Visual acuity loss depends on location, severity and duration of macular edema. We present a case report of a patient with non-infectious uveitis and recurrent episodes of bilateral macular edema. This patient was refractory to systemic corticosteroids, intravitreal dexamethasone implant and several immunosuppressant drugs. Afterwards, we decided to change to fluocinolone acetonide implant. We present the results with the latest therapeutical option.
Methods
56-year-old patient visited retinal specialist due to a decrease in visual acuity in both eyes (OU). Best Corrected Visual Acuity (BCVA) was 70 letters in left eye (OS) and 60 letters in right eye (OD). Central macular thickness (CMT) was 593 µm in OS and 769 µm in OD previous to fluocinolone acetonide implant. Biomicroscopy showed Tyndall + in OU and fundus with vitritis + and bilateral macular edema confirmed by OCT. A systemic study was performed being completely negative. We decided to start treatment with systemic corticosteroids and dexamethasone implants in OU, however macular edema recurred. We changed to other therapeutical options: Methotrexate, Adalimumab, Mycophenolate and Tocilizumab. During this period, we injected 6 and 5 intravitreal dexamethasone implants in right and left eye, respectively. The patient developed cataracts in OU and was operated without complete macular edema resolution. We decided to use intravitreal fluocinolone acetonide insert in OU.
Results
After 14 y 18 months (OD and OS) from intravitreal fluocinolone acetonide injection, her visual acuity was 80 letters in OD and 85 letters in OS (BCVA). CMT decreased to 212 and 269 µm in OS and OD, respectively. Regarding systemic therapies, they no were necessary to control patient.
Conlusions
After 14 y 18 months (OD and OS) from intravitreal fluocinolone acetonide injection, her visual acuity was 80 letters in OD and 85 letters in OS (BCVA). CMT decreased to 212 and 269 µm in OS and OD, respectively. Regarding systemic therapies, they no were necessary to control patient.
Financial Disclosure
The authors report no conflicts of interest in this work
Comments
-